Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IEC 2021 | GABA suppressing drugs in epilepsy treatment

James Clement • 20 Aug 2021
IEC 2021
Epilepsy Bumetanide

James Clement, PhD, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, discusses the evidence supporting γ-Aminobutyric acid (GABA) suppressing drugs in epilepsy treatment. Dr Clement describes studies showing that bumetanide, a drug suppressing GABA activity, was able to restore the synaptic function in mouse models with autism and can be helpful in epilepsy treatment. This interview took place during the 34th International Epilepsy Congress, 2021.

More from James Clement

0:46
The next steps in autism treatment: gene therapy
James Clement • 20 Aug 2021
1:45
Upcoming clinical trials for small molecules to treat autism spectrum disorder
James Clement • 20 Aug 2021
1:56
GABAergic signaling in autism spectrum disorders
James Clement • 20 Aug 2021

Related Videos

4:17
Update from the X-TOLE open label extension study of XEN1101 in focal epilepsy
Jacqueline French • 16 Apr 2024
2:46
Multidisciplinary care for improving treatment of rare epilepsies
Simona Balestrini • 3 Jul 2023
1:08
Navigating challenges in multidisciplinary care for rare epilepsies
Simona Balestrini • 3 Jul 2023
5:54
SUDEP underestimated as a cause of mortality in older adults with epilepsy
Ifrah Zawar • 21 Dec 2023
The content of VJNeurology is intended for healthcare professionals